Skip to main content

A Microplate-based Platform with Immobilized Human Glutathione Transferase A1-1 for High-throughput Screening of Plant-origin Inhibitors

Buy Article:

$68.00 + tax (Refund Policy)

Background: Glutathione transferases (GSTs) catalyze the conjugation of glutathione (GSH) to endogenous and xenobiotic electrophilic compounds and have been involved in the development of resistance toward cancer chemotherapeutic drugs and in the etiology, pathology and progression of several other diseases. In the present work, the human isoenzyme GSTA1-1 (hGSTA1-1) was used to assemble a microplate-based platform for high-throughput screening of natural productbased inhibitors from plant extracts.

Methods: The enzyme was immobilized using sol-gel chemistry and deposited as a layer at the bottom surface of 96-well format ELISA microplate. The sensing signal was based on the inhibition of the colorimetric reaction between 1-chloro-dinitrobenzene (CDNB) and GSH, catalyzed by the sol-gel entrapped enzyme.

Results: As a proof of concept, the system was used for screening aqueous extracts from medicinal and aromatic plants with excellent reproducibility (approximately 95%).

Conclusion: The operational simplicity and accuracy of this system, suggest that it can be explored as a bioanalytical tool with potential use in drug design and development efforts for finding new sources of GST inhibitors useful in chemomodulation of cancer drugs.

Keywords: Drug design; cancer; enzyme inhibitor; glutathione transferase; high-throughput screening; immobilized enzyme

Document Type: Research Article

Publication date: 01 September 2018

This article was made available online on 08 November 2018 as a Fast Track article with title: "A Microplate-based Platform with Immobilized Human Glutathione Transferase A1-1 for High-throughput Screening of Plant-origin Inhibitors".

More about this publication?
  • Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in both pre-clinical and clinical areas of Pharmaceutical Biotechnology. Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content